Peptide Schedule
Desmopressin (DDAVP)9 residuesCYFQNCPRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Desmopressin (DDAVP)
Benefits
About Desmopressin (DDAVP)
Desmopressin (DDAVP) is a first-line synthetic vasopressin analog approved by the FDA for the management of central diabetes insipidus, primary nocturnal enuresis in patients aged 6 years and older, and as a hemostatic agent in mild hemophilia A and type 1 von Willebrand disease. Originally developed in the 1970s, desmopressin represented a breakthrough in peptide engineering by selectively targeting vasopressin V2 receptors in the renal collecting ducts while minimizing activation of V1a receptors responsible for vasoconstriction. This selectivity allows clinicians to harness its potent antidiuretic effects without the cardiovascular side effects associated with native vasopressin. In the kidney, desmopressin binds to V2 receptors on the basolateral membrane of principal cells in the collecting duct, triggering a Gs-protein/adenylate cyclase/cAMP signaling cascade that promotes translocation of aquaporin-2 water channels to the apical membrane. This dramatically increases water reabsorption, concentrates the urine, and reduces urine output — effectively replacing the missing or insufficient endogenous ADH in patients with central diabetes insipidus. For hemostatic indications, desmopressin acts on endothelial V2 receptors to stimulate exocytosis of Weibel-Palade body contents, rapidly releasing stored von Willebrand factor (VWF) multimers and factor VIII into the circulation. This can raise factor VIII levels 3- to 5-fold within 30 to 60 minutes, providing sufficient hemostatic coverage for minor surgeries and bleeding episodes without the need for blood product transfusions. This nontransfusional approach has transformed the management of mild bleeding disorders. Desmopressin is available in multiple formulations: the injectable form (4 mcg/mL for IV or subcutaneous use), intranasal spray (Stimate at 1.5 mg/mL for hemostatic use, or standard 0.1 mg/mL nasal spray for diabetes insipidus), and oral tablets (0.1 mg and 0.2 mg). The injectable route offers near-complete bioavailability and is the preferred route in clinical and research settings for precise dosing.
Who Should Consider Desmopressin (DDAVP)
- Patients with central diabetes insipidus requiring ADH replacement
- Children and adults with primary nocturnal enuresis unresponsive to behavioral therapy
- Patients with mild hemophilia A (factor VIII levels 5-50%)
- Patients with type 1 von Willebrand disease requiring hemostatic support
- Surgical patients needing perioperative hemostasis without blood products
How Desmopressin (DDAVP) Works
Desmopressin exerts its therapeutic effects primarily through selective agonism of vasopressin V2 receptors (V2R), a Gs-protein coupled receptor expressed on the basolateral membrane of principal cells in the renal collecting duct and on vascular endothelial cells. Structural modifications — deamination of cysteine at position 1 and substitution of L-arginine with D-arginine at position 8 — confer approximately 10-fold greater antidiuretic potency compared to native vasopressin, a significantly prolonged half-life, and minimal affinity for V1a receptors (which mediate vasoconstriction). In the kidney, V2R activation triggers adenylate cyclase, increasing intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA). PKA phosphorylates aquaporin-2 (AQP2) water channel proteins stored in intracellular vesicles, prompting their translocation and insertion into the apical membrane of collecting duct cells. This creates a water-permeable pathway that allows osmotic reabsorption of water from the tubular lumen back into the hypertonic medullary interstitium, dramatically concentrating the urine and reducing urine volume. For hemostatic applications, desmopressin binds V2 receptors on vascular endothelial cells, activating the same cAMP/PKA cascade to trigger exocytosis of Weibel-Palade bodies. These specialized secretory organelles store large von Willebrand factor (VWF) multimers and factor VIII. Release of these contents rapidly elevates circulating VWF and factor VIII levels, enhancing platelet adhesion and the intrinsic coagulation cascade. This mechanism makes desmopressin a valuable hemostatic agent in patients with mild hemophilia A and type 1 von Willebrand disease.
What to Expect
Onset of antidiuretic effect following SC/IV administration; initial reduction in urine output begins
Peak plasma levels achieved; factor VIII and VWF levels peak at 3- to 5-fold above baseline for hemostatic use
Maximum urine concentration achieved; antidiuretic effect fully established
Duration of antidiuretic effect; urine output returns toward baseline as drug is cleared
Stable dose titration for diabetes insipidus achieved; consistent control of urine volume and serum sodium
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1mcg | Daily |
| Moderate | 2mcg | 2x Daily |
| Aggressive | 4mcg | 2x Daily |
Note: Desmopressin (1-desamino-8-D-arginine vasopressin, DDAVP) is a synthetic analog of the natural antidiuretic hormone vasopressin (ADH). It was first approved by the FDA in 1978 and remains a cornerstone treatment for central diabetes insipidus, primary nocturnal enuresis, and mild hemophilia A/von Willebrand disease type 1. Desmopressin is structurally modified from native vasopressin with deamination at position 1 and substitution of D-arginine at position 8, granting it dramatically enhanced antidiuretic potency (approximately 10-fold greater than vasopressin), a prolonged duration of action, and negligible vasopressor activity. It is available as injectable (IV/SC), intranasal spray, and oral tablet formulations. The injectable form is supplied as a 4 mcg/mL solution and does not require reconstitution. Fluid intake must be carefully managed during therapy to prevent hyponatremia and water intoxication, the most serious potential adverse effect.
How to Inject Desmopressin (DDAVP)
For central diabetes insipidus, the recommended starting dose is 2-4 mcg/day administered as one or two divided subcutaneous or intravenous injections. Dose is individually titrated based on urine output, urine osmolality, and serum sodium levels. For hemostatic use in hemophilia A or von Willebrand disease, the standard dose is 0.3 mcg/kg body weight diluted in 50 mL normal saline and infused IV over 15-30 minutes, or administered subcutaneously. Peak factor VIII and VWF levels are typically achieved within 30-90 minutes post-dose. A test dose should be administered to confirm adequate hemostatic response before relying on desmopressin for surgical coverage. Do not administer more frequently than every 48 hours for hemostatic indications to avoid tachyphylaxis. Fluid intake should be limited to the minimum required to satisfy thirst during therapy. Monitor serum sodium before starting and periodically during treatment.
Cycling Protocol
Desmopressin is used continuously for diabetes insipidus (no cycling needed) or on an as-needed basis for hemostatic indications. For hemophilia A/VWD, doses should be spaced at least 48 hours apart to avoid tachyphylaxis. Serum sodium should be monitored regularly, especially when initiating therapy or adjusting dose. Fluid intake must be restricted to minimize hyponatremia risk.
Pharmacokinetics
Source: Mean t½ 3.1 hours (range 2.7-4.6 h) in healthy subjects after subcutaneous injection (Eur J Clin Pharmacol 1988; PMID 3141199)
Loading the interactive decay curve.
Side Effects
The most clinically significant adverse effect of desmopressin is hyponatremia (low blood sodium), which results from its antidiuretic mechanism causing water retention that dilutes serum sodium. If unrecognized, severe hyponatremia can lead to headache, nausea, vomiting, lethargy, confusion, seizures, coma, and in rare cases death. Risk is greatest in patients with excessive fluid intake, the elderly, young children, and those on medications that impair water excretion. Other reported adverse reactions include facial flushing (particularly with IV administration), headache, dizziness, nausea, abdominal cramps, and nasal congestion (with intranasal use). Mild injection site reactions may occur with subcutaneous dosing. Rare but serious adverse events include allergic reactions including anaphylaxis, transient blood pressure changes, and thrombotic events in susceptible individuals. Tachyphylaxis (reduced response with repeated doses) has been observed with the hemostatic indication when doses are given at intervals shorter than 48 hours.
Contraindications
- Hyponatremia or history of hyponatremia
- Moderate to severe renal impairment (CrCl < 50 mL/min)
- Known hypersensitivity to desmopressin acetate or any excipients
- Primary nocturnal polydipsia or conditions predisposing to excessive fluid intake
- Concomitant use of loop diuretics or systemic glucocorticoids (increased hyponatremia risk)
- Pregnancy — FDA Category B; use only if clearly needed
- Breastfeeding — desmopressin is excreted in breast milk in negligible amounts; however, infants should be monitored for signs of hyponatremia
Drug Interactions
- Carbamazepine, SSRIs, TCAs, chlorpromazine, and NSAIDs may potentiate the antidiuretic effect and increase hyponatremia risk
- Loop diuretics and systemic/inhaled glucocorticoids may increase the risk of water intoxication and hyponatremia
- Loperamide may increase desmopressin plasma concentrations up to 3-fold via intestinal absorption effects
- Demeclocycline and lithium may attenuate the antidiuretic response to desmopressin
Storage & Stability
Molecular Profile
Related Peptides
References
- Desmopressin: a nontransfusional treatment of hemophilia and von Willebrand disease (Haemostasis 1994)Review
- Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses (J Lab Clin Med 1988)PubMed 3127916
- Pharmacokinetics and haematological effects of desmopressin (Eur J Clin Pharmacol 1988)PubMed 3141199
- FDA-Approved DDAVP Injection Prescribing Information (2022)FDA Label
- The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007)Review